AI Revolutionizes Embryo Selection in IVF

Nova IVF Fertility is pioneering the integration of AI in its labs to enhance embryo selection in IVF treatments. Partnering with Kai Health, the AI system, Vita Embryo, aims to improve precision and address ethical concerns over multiple pregnancies, increasing selection accuracy by 12 percent.

Nova IVF Fertility has announced a significant advancement in fertility treatment by integrating Artificial Intelligence into their IVF laboratories. This initiative is aimed at enhancing the precision of embryo selection—an essential element in IVF procedures.

The CEO, Shobhit Agarwal, highlighted the ethical benefits, noting that greater precision could reduce the number of embryos needed for transfer and subsequently minimize the risk of multiple pregnancies. This technological partnership is with South Korea's AI firm, Kai Health, known for its Vita Embryo assessment system.

According to Hyejun Lee, CEO of Kai Health, research has shown that AI can increase the accuracy of embryo selection by 12 percent. The roll-out of Vita Embryo is planned across 120 Nova IVF Fertility centers in 65 cities, marking a transformative step in fertility treatment.